Mining emerging biomedical literature for understanding disease associations in drug discovery.

Systematically evaluating the exponentially growing body of scientific literature has become a critical task that every drug discovery organization must engage in in order to understand emerging trends for scientific investment and strategy development. Developing trends analysis uses the number of publications within a 3-year window to determine concepts derived from well-established disease and gene ontologies to aid in recognizing and predicting emerging areas of scientific discoveries relevant to that space. In this chapter, we describe such a method and use obesity and psoriasis as use-case examples by analyzing the frequency of disease-related MeSH terms in PubMed abstracts over time. We share how our system can be used to predict emerging trends at a relatively early stage and we analyze the literature-identified genes for genetic associations, druggability, and biological pathways to explore any potential biological connections between the two diseases that could be utilized for drug discovery.

[1]  Samuel Szomstein,et al.  Psoriasis Remission after Laparoscopic Roux-En-Y Gastric Bypass for Morbid Obesity , 2004, Obesity surgery.

[2]  Steven R Feldman,et al.  Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. , 2012, Dermatology online journal.

[3]  J. Gelfand,et al.  The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. , 2009, Journal of the American Academy of Dermatology.

[4]  E. Christophers,et al.  Disease concomitance in psoriasis. , 1995, Journal of the American Academy of Dermatology.

[5]  Judith A. Blake,et al.  The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse , 2011, Nucleic Acids Res..

[6]  M. Fontana,et al.  The surgical treatment of metabolic disease and morbid obesity. , 2010, Gastroenterology clinics of North America.

[7]  P. Achurra,et al.  Psoriasis Following Bariatric Surgery: Clinical Evolution and Impact on Quality of Life on 10 patients , 2012, Obesity Surgery.

[8]  P. Sanseau,et al.  Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.

[9]  Amy E Foxx-Orenstein,et al.  Gastrointestinal symptoms and diseases related to obesity: an overview. , 2010, Gastroenterology clinics of North America.

[10]  F. Collins,et al.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.

[11]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[12]  N. Yawalkar,et al.  Expression of interleukin-12 is increased in psoriatic skin. , 1998, The Journal of investigative dermatology.

[13]  Richard N Bergman,et al.  Gastrointestinal hormones and bariatric surgery‐induced weight loss , 2013, Obesity.

[14]  Francesco Rubino,et al.  Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. , 2010, Annual review of medicine.

[15]  Thomas C. Wiegers,et al.  Text Mining Effectively Scores and Ranks the Literature for Improving Chemical-Gene-Disease Curation at the Comparative Toxicogenomics Database , 2013, PloS one.

[16]  K. Shah,et al.  Diagnosis and Treatment of Pediatric Psoriasis: Current and Future , 2013, American Journal of Clinical Dermatology.

[17]  Luis Garcia,et al.  Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. , 2013, JAMA.

[18]  David B. Searls,et al.  Can literature analysis identify innovation drivers in drug discovery? , 2009, Nature Reviews Drug Discovery.

[19]  Miguel A. Andrade-Navarro,et al.  Automatic Annotation for Biological Sequences by Etraction of Keywords from MEDLINE Abstracts: Development of a Prototype System , 1997, ISMB.

[20]  Christian Gieger,et al.  Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis , 2010, Nature Genetics.

[21]  Laura K Ferris,et al.  Anti-cytokine therapy in the treatment of psoriasis. , 2013, Cytokine.

[22]  Steven R Feldman,et al.  Combination therapy for psoriasis in the United States. , 2013, Journal of drugs in dermatology : JDD.

[23]  Gregory D. Schuler,et al.  Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.

[24]  G. Derosa,et al.  Anti-obesity drugs: a review about their effects and their safety , 2012, Expert opinion on drug safety.

[25]  J. Koo,et al.  An evidence-based review of skin cancer rates on biologic therapies , 2012, The Journal of dermatological treatment.

[26]  G. Krueger,et al.  Psoriasis--recent advances in understanding its pathogenesis and treatment. , 2005, Journal of the American Academy of Dermatology.

[27]  Giampiero Girolomoni,et al.  Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. , 2008, The American journal of clinical nutrition.

[28]  Andrea B Troxel,et al.  Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. , 2012, Archives of dermatology.

[29]  Mayte Suárez-Fariñas,et al.  Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis , 2012, The Journal of investigative dermatology.

[30]  R. Leibel,et al.  Molecular physiology of weight regulation in mice and humans , 2008, International Journal of Obesity.

[31]  André Reis,et al.  Identification of low-frequency TRAF3IP2 coding variants in psoriatic arthritis patients and functional characterization , 2012, Arthritis Research & Therapy.

[32]  James T. Elder,et al.  Comparison of MHC class I risk haplotypes in Thai and Caucasian psoriatics shows locus heterogeneity at PSORS1. , 2010, Tissue antigens.

[33]  S. Waldman,et al.  Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy , 2010, Clinical pharmacology and therapeutics.

[34]  Carlo Tomino,et al.  Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis , 2008, Dermatology.

[35]  Supriyo De,et al.  Systematic analysis, comparison, and integration of disease based human genetic association data and mouse genetic phenotypic information , 2010, BMC Medical Genomics.

[36]  Suyan Tian,et al.  Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease , 2012, PloS one.

[37]  William H. Majoros,et al.  Genomics and natural language processing , 2002, Nature Reviews Genetics.

[38]  Eric W Hossler,et al.  Gastric bypass surgery improves psoriasis. , 2011, Journal of the American Academy of Dermatology.

[39]  C. Fiehn,et al.  Methotrexate transport mechanisms: the basis for targeted drug delivery and ß-folate-receptor-specific treatment. , 2010, Clinical and experimental rheumatology.

[40]  R W Groves,et al.  Detection of circulating adhesion molecules in erythrodermic skin disease. , 1995, Journal of the American Academy of Dermatology.

[41]  David Carling,et al.  AMPK, insulin resistance, and the metabolic syndrome. , 2013, The Journal of clinical investigation.

[42]  Alan Menter,et al.  Psoriasis and the metabolic syndrome. , 2008, Journal of drugs in dermatology : JDD.

[43]  Scott A Waldman,et al.  New advances in models and strategies for developing anti-obesity drugs , 2013, Expert opinion on drug discovery.

[44]  T. Jenssen,et al.  A literature network of human genes for high-throughput analysis of gene expression , 2001 .

[45]  Padmini Srinivasan,et al.  Distilling Conceptual Connections from MeSH Co-Occurrences , 2004, MedInfo.

[46]  Jennifer E Towne,et al.  The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. , 2013, The Journal of investigative dermatology.

[47]  F. Anania,et al.  The Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism , 2013, Seminars in Liver Disease.

[48]  Christopher R. Lindholm,et al.  A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats , 2012, Journal of Physiology and Biochemistry.

[49]  S. Piaserico,et al.  Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study , 2007, The British journal of dermatology.

[50]  Luis Puig,et al.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.

[51]  Daniel Hanisch,et al.  Playing Biology's Name Game: Identifying Protein Names in Scientific Text , 2002, Pacific Symposium on Biocomputing.

[52]  J. Prins,et al.  The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. , 1997, Journal of immunology.

[53]  Michal Magid-Slav,et al.  Gastrointestinal weight-loss surgery: glimpses at the molecular level. , 2013, Drug discovery today.

[54]  Giampiero Girolomoni,et al.  Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. , 2005, European journal of dermatology : EJD.

[55]  Barend Mons,et al.  In silico discovery and experimental validation of new protein–protein interactions , 2011, Proteomics.

[56]  Donny Wong,et al.  The pharmaceutical market for obesity therapies , 2012, Nature Reviews Drug Discovery.

[57]  J. Gelfand,et al.  Is there truly a risk of lymphoma from biologic therapies? , 2009, Dermatologic therapy.

[58]  P. O’Brien,et al.  Bariatric surgery: Mechanisms, indications and outcomes , 2010, Journal of gastroenterology and hepatology.

[59]  Michael Hinckley,et al.  Impact of obesity and smoking on psoriasis presentation and management. , 2005, Archives of dermatology.

[60]  Barend Mons,et al.  Generic Information Can Retrieve Known Biological Associations: Implications for Biomedical Knowledge Discovery , 2013, PloS one.

[61]  Carsten Carlberg,et al.  Current status of vitamin D signaling and its therapeutic applications. , 2012, Current topics in medicinal chemistry.

[62]  James T. Elder,et al.  Genetic associations of psoriasis in a Pakistani population , 2013, The British journal of dermatology.

[63]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[64]  Norbert Reider,et al.  A marriage of two “Methusalem” drugs for the treatment of psoriasis? , 2013, Dermato-endocrinology.

[65]  Zhen Hu,et al.  BMC Bioinformatics BioMed Central Methodology article CLEAN: CLustering Enrichment ANalysis , 2009 .

[66]  J. Gudjonsson,et al.  Analysis of global gene expression and genetic variation in psoriasis. , 2007, Journal of the American Academy of Dermatology.

[67]  David J Margolis,et al.  Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. , 2004, The journal of investigative dermatology. Symposium proceedings.

[68]  Honghui Zhou,et al.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab , 2011, Nature Biotechnology.

[69]  L. Skov,et al.  Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti‐inflammatory drugs: a Danish real‐world cohort study , 2013, Journal of internal medicine.

[70]  Hagit Shatkay,et al.  Genes, Themes, and Microarrays: Using Information Retrieval for Large-Scale Gene Analysis , 2000, ISMB.

[71]  Joyce A. Mitchell,et al.  Gene Indexing: Characterization and Analysis of NLM's GeneRIFs , 2003, AMIA.

[72]  Philippe Sanseau,et al.  The role of translational bioinformatics in drug discovery. , 2011, Drug discovery today.

[73]  E. Finkelstein,et al.  Annual medical spending attributable to obesity: payer-and service-specific estimates. , 2009, Health affairs.

[74]  Pál Pacher,et al.  Modulating the endocannabinoid system in human health and disease – successes and failures , 2013, The FEBS journal.

[75]  David B. Searls,et al.  Literature mining in support of drug discovery , 2008, Briefings Bioinform..

[76]  Hong Liang Tey,et al.  Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents , 2013, BioDrugs.

[77]  L. Kaplan,et al.  Pharmacologic therapies for obesity. , 2010, Gastroenterology clinics of North America.

[78]  David J. Margolis,et al.  Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom , 2011, The Journal of investigative dermatology.

[79]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[80]  P. O'Neil,et al.  Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study , 2012, Obesity.